AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01909440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01909440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03167385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: oral intake of Apatinib Mesylate 500mg once a day until progression of diesase or severe adverse effect
Study NCT04472611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) and Colchicine+Rosuvastatin
Description: Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
Study NCT03908333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 25, 37.5, 56.25 or 75 grams/m2
Study NCT03908333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel protein-bound
Description: 125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
Study NCT03908333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 in 500 mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
Study NCT03908333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 in 500 mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
Study NCT02455921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine - atropine
Description: Efficacy, safety and effect on cognitive and behavioural function
Study NCT02455921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Efficacy, safety and effect on cognitive and behavioural function
Study NCT00454714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single dose Sildenafil
Description: Application of a single dose Sildenafil
Study NCT00454714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single dose placebo
Description: Application of a single dose placebo
Study NCT02458716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Assisted Radical Prostatectomy
Description: Undergo RARP
Study NCT02458716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional open retropubic radical prostectomy
Description: Undergo conventional open RRP
Study NCT02458716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02458716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02458716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
Description: LHRH agonist or antagonist (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
Study NCT01778790 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation with Activa PC Multi-program Neurostimulator
Description: Device: DBS 130 Hertz (Hz) frequency, 90us pulsewidth, 4 Volt (V) currency Amplitude~Device: DBS - No Stimulation (Sham) 130 Hertz (Hz)frequency, 90us pulsewidth, 0 Volt (V) currency Amplitude
Study NCT01778790 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation with Activa PC Multi-program Neurostimulator
Description: Device: DBS 130 Hertz (Hz) frequency, 90us pulsewidth, 4 Volt (V) currency Amplitude~Device: DBS - No Stimulation (Sham) 130 Hertz (Hz)frequency, 90us pulsewidth, 0 Volt (V) currency Amplitude
Study NCT02837900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPX-100 200 mg 4 times weekly for 4 weeks
Description: Ea. subject will received active TPX-100 200mg in the Left knee
Study NCT02837900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 200 mg 4 times weekly for 4 weeks
Description: Ea. subject will received active TPX-100 200mg in the Left knee
Study NCT02837900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPX-100 200 mg 4 times weekly for 4 weeks
Description: TPX-100 100mg Right
Study NCT02837900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 200 mg 4 times weekly for 4 weeks
Description: TPX-100 100mg Right
Study NCT03930836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand Arm Bimanual Intensive Therapy Including Lower Extremities
Description: Intensive intervention focusing on a constant bimanual coordination with a lower extremities and trunk control stimulation during play and functional activities. 50% of therapeutic time will be performed using the new interactive interface
Study NCT03930836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Arm Bimanual Intensive Therapy Including Lower Extremities
Description: Intensive intervention focusing on a constant bimanual coordination with a lower extremities and trunk control stimulation during play and functional activities. 50% of therapeutic time will be performed using the new interactive interface
Study NCT03930836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical and occupational therapy
Description: Conventional therapy (physical and occupational therapy) is mainly based on neurodevelopmental therapeutic principles. 50% of therapeutic time will be performed using the new interactive interface
Study NCT04335643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEACH
Description: TEACH is a remotely delivered psychological intervention. It consists of six one-hour weekly sessions that are HIPAA compliant and conducted over video conferencing.
Study NCT01442246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin Acetate
Description: Leuprorelin Acetate 45 mg, one injection every 6 months for 24 months
Study NCT04685798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging magnetic resonance imaging
Description: The research MRI study of the head and neck will be performed on a Siemens 3T MRI Scanner system
Study NCT04685798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Description: Standard of care
Study NCT00777712 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Blood will be drawn from subjects once and VAC sponge will be collected (which is normally discarded material per standard of care).
Study NCT05072418 — intervention group
Intervention type: BEHAVIORAL
Intervention: Eye-opened and Eye-closed
Description: The participants were instructed to perform six 60-second trials (2 conditions × 3 trials) of maintaining an upright stance on a force plate (Kistler Type 9260A, Switzerland) under the eyes open (EO) and eyes closed (EC) conditions. The order of EO and EC was alternated for each participant, and half of the subjects began with the EO (or EC) condition. For both conditions, the participants stood with their feet 1 cm apart on a force plate and their arms relaxed comfortably at their sides.
Study NCT02520817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: 175 mg zinc gluconate, 50000 IU vitamin A, 500 mg vitamin C and 100 mg vitamin E once daily plus lactulose; dose 30-60 ml/day for 3 months
Study NCT02520817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Lactulose
Study NCT03662958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutrate
Description: a novel leuprolide acetate 3.75mg depot
Study NCT03662958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enantone
Description: market reference leuprolide acetate 3.75 mg depot
Study NCT02349633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06747775
Study NCT02349633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Study NCT02349633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Study NCT00303823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00303823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given orally
Study NCT00303823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00303823 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04349891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electroacupuncture
Description: Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
Study NCT04349891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TEA
Description: Sham will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
Study NCT00637078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide
Description: initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination
Study NCT03422835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: R-TME
Description: Conventional Robotic Total Mesentery Excision
Study NCT03422835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R-TaTME
Description: Robotic Transanal Total Mesentery Excision
Study NCT02284204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam, Ketamine and Sevoflurane
Description: The combination of these three drugs were administered for the children of the intervention group in a attempt to improve the behavioral control. Midazolam and ketamine orally, sevoflurane inhaled.
Study NCT02284204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam and Ketamine
Description: The combination of these two drugs were administered orally for the children of the control group.
Study NCT03122041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Study NCT03122041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Study NCT02162550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bydureon
Description: once weekly injection
Study NCT02162550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once weekly injection
Study NCT01003158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: Tablet Oral bid
Study NCT01003158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV once weekly for 3 weeks followed by a week off
Study NCT02259673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fun exercise
Description: Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises (including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)
Study NCT02259673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fun exercise
Description: Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises~(including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)
Study NCT01488045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 50µg of Fentanyl. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Fentanyl in no more than 50µg increments. increments.
Study NCT01488045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be administered IV according to standard procedure for colonoscopy. The initial bolus of propofol will be up to 60 mg IV. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more sedation in 10-20 mg boluses.
Study NCT01488045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 2 mg of Midazolam. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Midazolam in no more than 2 mg increments.
Study NCT02541812 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: A non-invasive method for brain stimulation
Study NCT02541812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: A non-invasive method for brain stimulation
Study NCT02159066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: Combination of LGX818 and MEK162 (Part I)
Study NCT02159066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Combination of LGX818 and MEK162 (Part I)
Study NCT02159066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: Combination of LGX818 + MEK162 + LEE011 (Part II)
Study NCT02159066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: Combination of LGX818 + MEK162 + BGJ398 (Part II)
Study NCT02159066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Combination of LGX818 + MEK162 + BKM120 (Part II)
Study NCT02159066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Combination of LGX818 + MEK162 + INC280 (Part II)
Study NCT01949935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mupirocin
Study NCT01949935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Study NCT02022137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red cereal bar
Description: Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
Study NCT02022137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green cereal bar
Description: Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
Study NCT02022137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White cereal bar
Description: Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
Study NCT03431298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise & movement control
Description: The aerobic exercise content is no different between the experimental group and the active comparator group.~The movement control is individual training which divided into fourths progressing sessions.~* First, lumbo-pelvic and hip dynamic direction control.~* Second, trunk muscle groups, hip muscle groups and thigh muscle groups extensibility control.~* Third, trunk muscle groups and hip muscle groups through range control.~* Fourth, functional movement control training
Study NCT03431298 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: The aerobic exercise will organized in groups. Each group has 6-8 persons. The exercise form is fixed at each time.~The description of exercise form is as below:~* 10 min Warm up~* 40 min Aerobic exercise (which focus on lower extremity muscle strengthening and increasing muscle endurance)~* 10 min Cool down
Study NCT03881839 — intervention group
Intervention type: OTHER
Intervention: emergency
Description: The objective of this research will be to assess, in patients presenting in an emergency department, the prior consultation of medical information on a website, the impact on the emergency consultation decision and the relevance of this consultation.
Study NCT04291846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459 fasted in P1, high-fat diet in P2
Description: SHR1459 administration in fasted condition in period 1, SHR1459 administration after high-fat diet in period 2
Study NCT04291846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459 high-fat diet in P1, fasted in P2
Description: SHR1459 administration after high-fat diet in period 1, SHR1459 administration in fasted condition in period 2
Study NCT03495830 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: Exploration of carotid bifurcation. Clamping of carotid artery and plaque removal with endarterectomy. Plaque is stored. Suture of artery with direct suture or patch.
Study NCT04958824 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic test
Description: Pharmacogenetic test results for Cytochrome P450 genes are examined for markers of variant metabolism.
Study NCT01620060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days
Study NCT05239052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer task intervention
Description: subject received programs for upper arm movement training with providing computer screen task activities
Study NCT05239052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional long-term care services
Description: stroke subjects with wheelchair users receive conventional long-term care services
Study NCT02609308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short leg cast
Description: Immobilization with short leg cast with a dorsiflexed foot for two weeks
Study NCT02609308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament
Study NCT03438617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer leaders. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer leaders will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer leaders and participants.
Study NCT00115440 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bononophenylalanine (BPA)-based BNCT
Description: Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
Study NCT02004730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABSORB implantation
Description: ABSORB implantation for long (> 24mm) single vessel disease
Study NCT03663829 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT00628121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 1, 2 or 3mg, subcutaneouly dosed with single dose
Study NCT01950858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Weight reduction
Study NCT01950858 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight reduction
Study NCT00890734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT003-QbG10
Description: subcutaneous injection
Study NCT00890734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study NCT00648336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine 50 mg
Description: 50mg, single dose fasting
Study NCT00648336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purinethol® Tablets 50 mg
Description: 50mg, single dose fasting
Study NCT00923520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMS 612
Description: DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
Study NCT01022736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.
Study NCT04664153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 ointment
Description: PF-07038124 ointment at 0.01% with QD dosing for 6 weeks
Study NCT04664153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: Vehicle ointment with QD dosing for 6 weeks
Study NCT04664153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle ointment
Description: Vehicle ointment with QD dosing for 6 weeks
Study NCT03383926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4.5cm suture
Description: Suture confection of the Tobacco-pouch of 4.5cm from the anal margin.